Skip to content

Prostate cancer care choices were linked to different changes in daily function

In a prospective cohort with low-risk disease, reported function stayed stable under active surveillance, while surgery and radiotherapy were linked to different declines.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

People undergoing active surveillance reported stable function, while those undergoing prostate removal reported meaningful declines in continence and sexual function. Radiotherapy was associated with a different pattern of difficulties. Because this was an observational cohort, the findings describe outcomes after different care choices without proving that those choices alone caused the differences.

Keep in mind

The groups were not randomly assigned. The abstract does not explain how differences between patients choosing each option were addressed or report cancer-control outcomes alongside these functional results.

THE NUMBERS, WITH CONTEXT

What researchers found

−18 points

Urinary continence score change after nerve-sparing surgery

EPIC-26 mean change from baseline to 12 months; this exceeded the study's threshold for a clinically important decline.

BJU Int, 2026 · Original source ↓

What patients reported

The questionnaire covered continence, urinary irritation or obstruction, bowel function, sexual function and hormonal symptoms. Researchers compared changes from baseline with thresholds intended to identify changes large enough to matter clinically.

Different patterns of change

Continence remained stable after radiotherapy, but urinary irritation or obstruction, bowel, hormonal and sexual scores declined meaningfully. Active surveillance was associated with stable scores across all measured domains, which describes function rather than cancer control.

CHECK THE ORIGINAL

The original publication

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer.

Al-Nader M, Kesch C, Mahmoud O et al.
BJU Int · 2026

PubMed ID
41698790
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.